Aberrant accumulation and activation of eosinophils and potentially mast cells (MCs) contribute to the pathogenesis of eosinophilic gastrointestinal diseases (EGIDs), including eosinophilic esophagitis (EoE), gastritis (EG), and gastroenteritis (EGE). Current treatment options such as diet restriction and corticosteroids have limited efficacy and are often inappropriate for chronic use. One promising new approach is to deplete eosinophils and inhibit MCs with a monoclonal antibody (mAb) against Siglec-8, an inhibitory receptor selectively expressed on MCs and eosinophils. Here, we characterize MCs and eosinophils from human EG and EoE biopsies using flow cytometry and evaluate the effects of an anti-Siglec-8 mAb using a novel Siglec-8 transgenic mouse model in which EG/EGE was induced by ovalbumin sensitization and intragastric challenge. Mast cells and eosinophils were significantly increased and activated in human EG and EoE biopsies compared to healthy controls. Similar observations were made in EG/EGE mice. In Siglec-8 transgenic mice, anti-Siglec-8 mAb administration significantly reduced eosinophils and MCs in the stomach, small intestine, and mesenteric lymph nodes, and decreased levels of inflammatory mediators. In summary, these findings suggest a role for both MCs and eosinophils in EGID pathogenesis and support the evaluation of anti-Siglec-8 as a therapeutic approach that targets both eosinophils and MCs.
Introduction 47
Eosinophilic gastritis (EG) and gastroenteritis (EGE) are rare diseases of the gastrointestinal (GI) tract, 48 affecting minimally 20 in 100,000 people worldwide (1) . Prevalence has likely been underestimated due 49 to the absence of a standard diagnosis and medical education (2, 3), but is reported to be highest in 50 children and adults ages 20-50 years, with a slightly higher incidence in men (1) . These conditions belong 51 to a larger spectrum of GI disorders known as eosinophilic gastrointestinal disorders (EGIDs), which are 52 characterized by eosinophilic infiltration of the GI tract and debilitating GI symptoms (i.e., abdominal 53 pain, nausea, vomiting, diarrhea, and dysphagia) (1) . Current EGID treatment options such as diet 54 restriction and corticosteroids have limited efficacy and are often inappropriate for chronic use. Thus, 55
there is a significant medical unmet need for novel targeted therapies. 56
In EG/EGE and other EGIDs, eosinophils are believed to be one of the principal effector cells responsible 57 for GI symptoms and disease pathogenesis (1) . While mast cells have been reported to be elevated in 58 eosinophilic esophagitis (EoE), their role in EG/EGE is less well understood, despite evidence that EGIDs 59 are atopic in nature (4-6). Development of EG and EGE is associated with a history of allergy, food 60 sensitivity, eczema, and seasonal asthma, implicating involvement of mast cells (1) . Furthermore, mast 61 cells and genes associated with the mast cell transcriptome are increased in EG patient tissue (7) . Despite 62 elevated numbers in EoE and EG, no further characterization of the role of the mast cell has been 63 performed in EGIDs. 64
Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a cell surface receptor that has emerged as a 65 promising therapeutic target for treatment of allergic and inflammatory diseases. Siglec-8 is an inhibitory 66 receptor that is found selectively on human eosinophils and mast cells (and to a lesser degree, on 67 basophils). Binding of a monoclonal antibody (mAb) to Siglec-8 induces apoptosis to activated 68 eosinophils and inhibits mast cell activation (8-10). Only one Siglec-8 targeted therapy, AK002, is 69 currently in clinical development for the treatment of allergic, inflammatory, and proliferative diseases 70 involving eosinophils and mast cells. AK002 is a humanized, non-fucosylated IgG1 anti-Siglec-8 mAb 71 that has been shown to deplete eosinophils via antibody-dependent cellular cytoxicity and apoptosis, and 72 inhibit mast cell function (8) . 73
Given the putative roles of eosinophils and mast cells in EGIDs, we sought to characterize these cell types 74 in EG patient tissue and to develop a mouse model of EG and EGE wherein the effect of an anti-Siglec-8 75 mAb could be evaluated. Here we show that mast cells and eosinophils are significantly increased and 76 activated in EG and EoE patient tissue biopsies compared to non-diseased tissue. Moreover, the increase 77 in mast cell numbers in these EGID biopsies was similar in degree to that of eosinophils, suggesting that 78 both of these cell types are involved in the pathology of EGIDs. To evaluate the potential activity of an 79 anti-Siglec-8 mAb in a mouse model of EG and EGE, we developed a novel transgenic mouse that 80 selectively expresses human Siglec-8 on mast cells, eosinophils and basophils, as is the case in humans 81 (11). Systemic sensitization and intragastric challenge with ovalbumin (OVA) induced significant 82 infiltration of eosinophils and mast cells in the stomach, small intestine and mesenteric lymph nodes 83 (MLNs), similar to human EG and EGE disease. Therapeutic administration of an anti-Siglec-8 mAb 84 significantly and selectively reduced eosinophils, mast cells, and inflammation in all of these GI tissues. 85
These data provide evidence that both mast cells and eosinophils contribute to EGID pathogenesis and 86 demonstrate that targeting of Siglec-8 suppresses eosinophil and mast cell involvement in an EG and EGE 87 mouse model, thus supporting further clinical investigation of this receptor as a therapeutic target in 88
EGIDs. 89
Results 90
EG and EoE tissues from patients have elevated numbers of both mast cells and eosinophils 91
Of the EGIDs, EoE is the most prevalent and well characterized, whereas much less is known about EG 92 and EGE. To gain greater understanding of the biology driving EG, we procured fresh gastric tissue from 93 patients with EG or non-diseased control subjects without a history of gastrointestinal disease 94 (Supplemental Table 1 ). Tissues were digested into single cell suspensions and immune cells were 95 characterized by flow cytometry (Figure 1 , A). To confirm that mast cells and eosinophils were correctly 96 identified in our gating strategy, we examined known surface markers for these cells within the individual 97 gating windows. Mast cells (CD45 + 7AAD -SSC Hi CD24 -CD16 -) expressed Siglec-8 and CD117 98 (Supplemental Figure 1 , A) and eosinophils (CD45 + 7AAD -SSC Hi CD24 + CD16 -) expressed Siglec-8, 99
CCR3, and CD11b (Supplemental Figure 1 , A). To further validate the gating strategy, we sorted mast 100 cells and eosinophils from their respective windows, followed by May-Grunwald Giemsa and H&E 101 staining, respectively. Cells sorted from the mast cell window routinely contained metachromatic granules 102 that were characteristic of mast cells (Supplemental Figure 1, B) . Similarly, >95% of cells sorted from the 103 eosinophil window displayed a bilobed nucleus and eosin-pink granules that resembled human 104 eosinophils (Supplemental Figure 1, B ). These data demonstrate that the gating strategy used in Figure 1A 105 correctly identifies mast cells and eosinophils in GI tissue. 106
As expected, EG tissues had significantly increased numbers of eosinophils compared to non-diseased 107 tissue (Figure 1, B ). In addition, we found that mast cells were increased by approximately 5-fold in EG 108 tissue compared to non-diseased tissue (Figure 1 , C). These data were confirmed in EG tissue using 109 additional flow cytometry surface markers for mast cells and eosinophils (Supplemental Figure 1 , C-E). 110
Interestingly, mast cells were elevated to a similar extent as eosinophils in EG patient tissues (8.9% vs. 111 9.3% of all CD45+ cells, respectively). In contrast, the percentage of neutrophils and monocytes was 112 reduced in EG tissue compared to non-diseased control tissue, whereas other immune cells, including T 113 cells remained unchanged (Figure 1, D) . 114
To determine whether these observations could be extended to other EGIDs, we processed and 115 characterized esophageal tissue from EoE patients. Consistent with findings in EG tissue, as well as 116 previously published findings, mast cells and eosinophils were significantly increased to a similar extent 117 compared to non-diseased esophageal tissue ( Figure 1 , E and F) (12-16). These data demonstrate that 118 both eosinophils and mast cells are markedly and proportionally elevated in both EG and EoE patient 119 tissue and validate our flow cytometry-based approach to quantitatively assess immune cells in fresh 120 human tissue. 121
Eosinophils and mast cells in EG and EoE tissue are in an activated state 122
To characterize the state of activation of eosinophils and mast cells from EG tissue, we examined the 123 expression of surface markers associated with activation by flow cytometry (Figure 2 Lastly, to determine if increased mast cell activation occurred in other EGIDs, we examined the same 136 markers on mast cells from EoE patient tissue. Compared to non-diseased esophageal mast cells, EoE 137 mast cells also had significantly higher expression of CD107a, CD63, and IgE (Supplemental Figure 2 , 138 E). These data demonstrate that eosinophils and mast cells are found in elevated numbers and in an 139 activated state in EG patient tissue. Furthermore, we show that mast cells from EoE patient tissues are 140 also activated and display increased levels of cell surface markers associated with degranulation, such as 141
CD107a. These findings suggest that increased mast cell activation may be a shared feature across EGIDs 142 and supporting a role for activated eosinophils and mast cells in EGID disease pathogenesis. 143
Siglec-8 transgenic mice express Siglec-8 on eosinophils, mast cells and basophils 144
Based on the data above demonstrating elevation and activation of eosinophils and mast cells in EG 145 patient tissue, we set out to evaluate the activity of an anti-Siglec-8 mAb in a murine disease model of EG 146 and EGE. Like other members of the CD33-related Siglecs, Siglec-8 appears to have evolved recently, 147 with close homologs found only in some primate species (11, 22) . Therefore, to examine the in vivo 148 activity of anti-Siglec-8 mAb, we generated a human Siglec-8-expressing transgenic mouse, distinct from 149 previously generated mice (e.g., ROSA26-Siglec-8 knock-in mice) (23, 24). Instead, Siglec-8 transgenic 150 founder mice were generated via the pronuclear microinjection of DNA (Supplemental Figure 3 
Anti-Siglec-8 mAb reduces OVA-induced eosinophilic infiltration in the stomach and intestinal tissues 184
To determine the timing for therapeutic treatment with an anti-Siglec-8 antibody in our EG and EGE 185 mouse, we examined eosinophils in the periphery, stomach, small intestine and MLNs after the third OVA 186 challenge on day 32 (Supplemental Figure 6 ). OVA-sensitized and -challenged mice had significantly 187 increased eosinophils in the stomach, MLNs, and blood compared to sham-treated mice on day 32 188 (Supplemental Figure 6 , A-C). Surprisingly, OVA-exposed mice did not have significantly increased 
Anti-Siglec-8 mAb reduces OVA-induced mast cell accumulation in the stomach and intestinal tissues 207
We also examined mast cell infiltration in the EG and EGE mouse model. Mast cells were identified in GI 208 preparations as viable, CD45 + , Lin -, CD117 + , FcεRI + cells by flow cytometry and expressed Siglec-8 209 (Supplemental Figure 5, B ). As seen with stomach tissue eosinophils, significantly increased mast cells 210 were found in the stomach, but not small intestine by day 32 in OVA-administered mice compared to 211 39, both stomach eosinophils and mast cells were significantly reduced in anti-Siglec-8 mAb-treated 232 mice, however the magnitude of decrease seen with eosinophils was greater than that of mast cells ( Figure  233 5, E-F). These data suggest that anti-Siglec-8 mAb treatment differentially reduces eosinophils and mast 234 cells in the GI tract, consistent with the unique cell-specific activities of Siglec-8 in eosinophils and mast 235
cells. 236
The faster and more extensive reduction of tissue eosinophils seen in anti-Siglec-8 mAb-treated mice 237 compared to mast cells on days 34 and 39 suggest that Siglec-8 mAb treatment may directly decrease 238 eosinophils in GI tissue. To evaluate this, we collected and cultured dissociated ex vivo stomach tissue 239 from OVA-challenged mice on day 39 overnight in the presence of either an anti-Siglec-8 mAb or isotype 240 control mAb, followed by analysis of eosinophils by flow cytometry. Anti-Siglec-8 mAb treatment of 241 dissociated stomach tissue led to significantly fewer eosinophils compared to isotype control-mAb-treated 242 tissue (Supplemental Figure 8 , C-E). Similarly, AK002 directly reduced human tissue eosinophils in ex 243 vivo lung tissue (8). These data suggest that Siglec-8 mAb treatment directly reduces GI tissue 244 eosinophils, consistent with the known apoptotic activity of Siglec-8. 245
Anti-Siglec-8 mAb reduces OVA-induced inflammation in the intestine and serum 246
Upon activation with IgE and allergen, mast cells and subsequently eosinophils elicit inflammatory 247 allergic effects via production of chemokines that drive a type 2 immune response. To evaluate these 248 responses and effects of anti-Siglec-8 mAb treatment in the EG and EGE mouse model, we quantified the 249 mRNA expression of known mediators implicated in driving type 2 inflammation in the small intestine. (14). To better define the role of mast cells and eosinophils in EG, we used flow cytometry to characterize 289 fresh gastric tissue from EG and non-diseased subjects at the single cell level and found that both 290 eosinophils and mast cells were selectively and significantly increased in EG gastric tissue. In addition, 291
we found significantly elevated levels of mast cells and eosinophils in tissue from EoE patients, 292 consistent with previously published findings (15, 16, 32, 33). Interestingly, we show that mast cells are 293 elevated by a similar magnitude as eosinophils in both EG and EoE tissue, a finding not previously 294
reported. Surprisingly, we found that the frequencies of neutrophils and monocytes were reduced in EG 295 tissue compared to non-diseased gastric tissue. While this observation could reflect differences in the type 296 of tissue examined (biopsy vs. resected tissue), it could also be related to the strong Th2 response 297 associated with EG. These hypotheses will be addressed in future studies. 298
Further evaluation of mast cells and eosinophils in human EG tissue showed that eosinophils from EG 299 tissue were activated, based on the expression of CD11b and CD49d (as previously described with EoE) 300 (17-19, 34). Additionally, mast cells from EG and EoE patient tissues displayed significantly increased 301 degranulation markers (CD107a and CD63) and surface-bound IgE, consistent with an atopic state. To 302 our knowledge, this is the first evidence demonstrating that mast cells in EG/EGE tissue are activated and 303 apparently undergoing degranulation, based on changes in surface marker expression. These results 304 suggest that, in addition to eosinophils, mast cells are key effector cells in EGID disease pathogenesis, 305
and that therapies that only affect one of these cell types may not fully address EGID pathogenesis. 306
Our analysis confirmed that Siglec-8 was highly expressed on human tissue eosinophils and mast cells, 307 which stands in contrast to the low expression levels of IL-5Rα. To explore the therapeutic potential of 308
Siglec-8, we used an EG and EGE disease model in Siglec-8 transgenic mice. Development of a 309 transgenic mouse was necessary due to the disparities between human Siglec-8 and its functional paralog 310 in mice, Siglec-F, most notably, differences in Siglec-8 and Siglec-F function and a lack of expression of 311
Siglec-F on murine mast cells (9). Sensitization and intragastric challenge with OVA led to a significant 312 increase in eosinophils and mast cells in stomach, intestinal, and MLN tissue, correlating with the human 313 ex vivo data described above, further implicating both eosinophils and mast cells in EG pathogenesis. 314
Treatment with an anti-Siglec-8 antibody reduced mouse eosinophils and mast cells across all GI tissues 315 assessed, as well as decreased blood eosinophils. In this model, GI tissue eosinophils were reduced to 316 sham (baseline) levels in anti-Siglec-8 mAb treated mice. Interestingly, a similar pattern of eosinophil 317 reduction to sham levels was also seen after anti-Siglec-F antibody treatment in two different EGID 318 mouse models (27, 35). These data suggest, but do not prove, that anti-Siglec-F/8 treatment may 319 preferentially reduce inflammatory eosinophils over the non-inflammatory, tissue-resident eosinophil 320 populations in the mouse. Given that the lifespan of murine intestinal eosinophils is estimated to be 321 greater than 7 days (36, 37), our data also suggests that anti-Siglec-8 mAb may elicit direct effects against 322 existing tissue eosinophils, rather than simply on their production. Indeed, ex vivo treatment with an anti-323
Siglec-8 mAb significantly reduced murine stomach tissue eosinophils compared to isotype control mAb-324 treated cells, consistent with our findings of AK002's effect on human tissue eosinophils (8). The 325 reduction of tissue eosinophils by anti-Siglec-8 mAb or AK002 in ex vivo tissue, where accessory cells 326 are absent, is most likely due to the direct, ADCC-independent induction of death of primed eosinophils. 327
Anti-Siglec-8 mAb treatment also significantly reduced the number of mast cells in stomach and small 328 intestinal tissue. As anti-Siglec-8 mAbs are known to have an inhibitory, rather than apoptotic, effect on 329 mast cells, the mechanism of reduction of mature mast cells in the intestine in our model is likely due to 330 the decreased recruitment of mast cell progenitors through reduced production of chemokines, including 331 CCL5 and CCL2 (8, 10). Indeed, the CCL2/CCR2 axis has been shown to be important in the recruitment 332 of mast cell progenitors in allergic airway inflammation (38), suggesting that CCL2 plays a role in the 333 recruitment of mast cell progenitors to inflamed GI tissue. Alternatively, anti-Siglec-8 mAb treatment 334 could directly decrease mast cell progenitors or inhibit pro-survival signaling pathways in mature mast 335 cells, resulting in reduced mature mast cell numbers over time. However, Siglec-8 expression is restricted 336 to mature mast cells and the turn-over of mast cells is thought to be in the range of months, suggesting 337 that mice would need to be dosed with an anti-Siglec-8 mAb for a longer period of time to allow for mast 338 cell turn-over (10, 39). The exact mechanism of Siglec-8 mediated mast cell reduction will be addressed 339 in future studies. Consistent with the apoptotic vs. inhibitory activity of Siglec-8 on eosinophils and mast 340 cells, respectively, we found that eosinophils were reduced faster and to a greater extent than mast cells in 341 anti-Siglec-8 mAb treated mice. These data may reflect the apoptotic activity of Siglec-8 on eosinophils, 342 and an inhibitory effect on mast cells. In support of Siglec-8 mediated mast cell inhibition in vivo, anti-343
Siglec-8 mAb treatment has recently been shown to inhibit IgE-mediated passive systemic anaphylaxis in 344 humanized mice (8). 345
Treatment with the anti-Siglec-8 mAb also reduced the expression of inflammatory cytokines and 346 chemokines in intestinal tissues and serum. We did not observe increased expression of the canonical Th2 347 mediators, IL-4, IL-13 and CCL11, despite significant production of OVA-specific IgE and IgG. The lack 348 of change in these Th2-driving cytokines may be attributed to the C57BL/6 background of the transgenic 349 mice (40, 41). Mice sensitized and challenged with OVA displayed increased expression of other 350 inflammatory cytokines and chemokines associated with type 2 inflammation, including CCL2, CCL5, 351 CCL17, IL-9 and CXCL1, in the intestine and serum. Many of these mediators have been implicated in 352 driving eosinophilic and mast cell infiltration in allergic asthma and food allergy models (42-44). The 353
OVA-mediated increase of cytokines and chemokines was significantly reduced by anti-Siglec-8 mAb, 354
suggesting that mast cells and/or eosinophils may drive their expression. Indeed, CCL2, CCL5 and IL-9 355 have been shown to be produced by mast cells as well as promote eosinophil recruitment (42, 45-49); 356 however, the role of these specific mediators in the stomach and small intestine remains to be elucidated. 357
Consistent with an overall reduction in allergen-induced GI inflammation, Siglec-8 mAb treated mice also 358 had decreased MLN weights compared isotype-treated mice. 359
In summary, we show that mast cells, as well as eosinophils, are significantly elevated and activated in 360 gastric tissue from patients with EG. Consistent with human disease, our mouse model of EG and EGE 361 also displayed infiltration of eosinophils and mast cells in GI tissues. Therapeutic treatment with an anti-362
Siglec-8 mAb significantly suppressed eosinophil and mast cell accumulation and intestinal 363 inflammation. Collectively, these findings suggest a role for both mast cells and eosinophils in EGID 364 pathogenesis and further support the evaluation of Siglec-8 as a new therapeutic approach to treat EGIDs. 365
Methods 366
Generation of Siglec-8 transgenic mice 367
Siglec-8 transgenic founder mice were generated via the pronuclear microinjection of DNA containing 368 Beginning on day 28, mice received a total of 6 intragastric OVA challenges every 2 days. Mice received 398 a single intraperitoneal (IP) dose of 5 mg/kg of either an anti-Siglec-8 mAb (mIgG2a, Allakos, Redwood 399 City, CA) or isotype-matched control mAb (mIgG2a, Biolegend) on day 32. Sham-treated mice were 400 systemically sensitized with OVA + alum but intragastrically challenged with phosphate-buffered saline 401 (PBS; Sigma). Mice were harvested on day 39 or as otherwise indicated. 402
Siglec-8 in vivo internalization study 403
Siglec-8 transgenic mice (8-10 weeks of age) were systemically dosed (IP) with 100 µg isotype control 404 (hIgG4, Eureka Therapeutics) or AK002-G4 (humanized hIgG4 anti-Siglec-8 mAb that does not have 405 ADCC activity) (8). After 48 hours, peripheral blood was collected and transgenic Siglec-8 and 406 endogenous Siglec-F expression was analyzed on eosinophils using flow cytometry. Conjugated 407 antibodies to non-cross-reactive epitopes were used to detect any remaining Siglec-8 (Allakos, Inc, 408
Redwood City, CA) or Siglec-F on the cell surface (Biolegend). 409
Human Tissue Collection 410
EG and EoE were diagnosed as ≥30 eosinophils/HPF in 5 HPFs in the gastric mucosa and ≥15 411 eosinophils/HPF in the esophagus without any other cause for the gastric/duodenal eosinophilia (e.g., 412 parasitic or other infection or malignancy). EGID tissue was collected and placed into Roswell Park 413
Memorial Institute (RPMI) with Penicillin Streptomycin (Sigma) at the University of Utah and shipped 414 overnight to Allakos on wet ice for flow cytometry analysis. Human esophageal and stomach tissue were 415 provided by the NCI Cooperative Human Tissue Network (CHTN) from subjects who expired from non-416 gastrointestinal diseases. Other investigators may have received specimens from the same tissue 417 specimens. All tissues were processed and analyzed approximately 24 hours after collection. 418
Blood and tissue sample processing 419
EDTA-treated anti-coagulated blood was collected by cardiac, tail, or submandibular vein bleeding. 420
Peritoneal cells were harvested in PBS. Both were obtained using an IACUC approved animal protocol. 421
Blood was processed by lysing red blood cells (RBCs) with ammonium-chloride-potassium buffer and 422 washed in PBS (Thermo Fisher Scientific, Waltham, MA) to obtain PBL. PBL were resuspended in 423 RPMI 1640 medium + 10% fetal bovine serum (FBS, Thermo Fisher Scientific, Waltham, MA). Human 424 and murine intestinal tissue was enzymatically and mechanically dissociated using the gentleMACs™ 425
Dissociator system (Miltenyi Biotec, Germany), according to the manufacturer's protocol. Cells derived 426 from tissue were then treated with RBC lysing buffer, washed in PBS and resuspended in RPMI 427 1640+10% low IgG FBS. Immediately after digestion, cell viability was examined using flow cytometry. 428
From biological fluids and dissociated tissues, only single-cell suspensions that had at least 70% viability 429 were used in subsequent experiments. 430
Flow cytometric analysis of blood and tissue 431
PBL from murine blood and single cells derived from tissue were obtained as described above. 432
Approximately 0.1-0.5 x 10 6 cells were stained/well in 96-well plates with mouse or human Fc blocking 433 reagents (BD Biosciences, Franklin Lakes, NJ) for 10 minutes at 4°C followed by incubation with 434 conjugated antibodies for 10 minutes at 4°C. Cells were then washed with fluorescence-activated cell 435 sorting buffer (0.1% bovine serum albumin in PBS), resuspended in fixative (1% paraformaldehyde in 436 
May-Grunwald Giemsa Stain 461
Human GI tissue was processed into single cells as described above. Following digestion, cells were 462 stained with 7AAD, CD45 BV421, CD16 FITC, and CD24 APCCy7 to identify mast cells and 463 eosinophils for flow cytometry. Mast cells (CD45+ 7AAD-SSCHi CD16-CD24-) and eosinophils 464 (CD45+ 7AAD-SSCHi CD16-CD24+) were sorted by FACS (Sony Biotechnology) into RPMI + 10% 465 FBS (Gibco). Approximately 80K mast cells and 100K eosinophils were sorted with greater than 95% 466 purity. Following sorting, cells were centrifuged for 5 min at 1200 RPM to create cell pellets and 467 resuspended for cytospin evaluation using a Shandon Cytospin 3 instrument. For May-Grunwald Giemsa 468 staining, the slides were then fixed in methanol for 90 seconds and stained with May-Grunwald Giemsa 469 stain (Newcomer Supply part #s 1210A and 1121A) according to the manufacturer's instructions. For 470 H&E staining, the slides were stained with Gill III hematoxylin, transferred to 4.25% acetic acid, and 471 dipped in eosin. Slides were evaluated by a pathologist, using an Olympus BX51 microscope, equipped 472 with a DP72 camera. Representative images were captured using CellSensEntry, v 1.18 (Olympus) at an 473 original magnification of 400x. 474
Cytokine, chemokine and OVA-specific IgE and IgG1 analysis in serum and tissue 475
RNA was isolated from homogenized mouse small intestinal tissue according to methods provided by the 476 manufacturer (Qiagen). cDNA was synthesized according to manufacturer's protocol (Thermo Fisher) 477 and qPCR was performed using SYBR green (Thermo Fisher) and pre-designed gene specific primers for 478 GAPDH, MCPT1, MBP, CCL17, CCL2, CCL5, CCL11, CCL24, IL4, IL5, and IL-13 (IDT). Relative gene 479 expression was calculated using the ΔΔCt method. Levels of cytokines and chemokines in mouse serum 480 were quantified using Luminex technology (Millipore). OVA-specific mouse IgE and IgG was quantified 481 by ELISA according to manufacturer's procedures (MD Bioproducts, St. Paul, MN). 482
Statistics 483
To determine statistical significance, nonparametric Mann Whitney U test, unpaired 2-tailed Student's t 484 test, 2-tailed t test with Sidak's post-test, or one-way ANOVA with Tukey's post-test for multiple 485 comparisons were performed using GraphPad Prism (GraphPad Software). A P value of 0.05 or less was 486 considered significant. 487
Study approval 488
The collection of human EGID biopsy tissue was approved by the University of Utah Institutional Review 489
Board (IRB# 00110127). The IRB approved protocol did not include collection of personal information 490 and medical history from patients besides meeting diagnostic criteria. All animal experiments were done 491 at Aragen Biosciences (Morgan Hill, CA) under an Institutional Animal Care and Use committee 492 protocol. For all studies, animals were randomly selected without formal pre-randomization, and 493 quantitative measurements were done without the opportunity for bias. 494 
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